Carney complex

Summary

Carney complex (MONDO:0015285) is a disease with 1 cohort gene and 4 clinical trials. Top therapeutic interventions include linsitinib.

At a glance

• Prevalence: <1 / 1 000 000 (Worldwide) [Orphanet-validated]
• Cohort genes: 1
• ClinVar variants: 5
• Phenotypes (HPO): 64
• Clinical trials: 4

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Cases/families		750	Worldwide	Validated
Point prevalence	<1 / 1 000 000		Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

64 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO ID	Term	Frequency
HP:0001580	Pigmented micronodular adrenocortical disease	Very frequent (80-99%)
HP:0000138	Ovarian cyst	Frequent (30-79%)
HP:0000845	Elevated circulating growth hormone concentration	Frequent (30-79%)
HP:0000866	Euthyroid multinodular goiter	Frequent (30-79%)
HP:0000870	Increased circulating prolactin concentration	Frequent (30-79%)
HP:0001003	Multiple lentigines	Frequent (30-79%)
HP:0001074	Atypical nevi in non-sun exposed areas	Frequent (30-79%)
HP:0003118	Increased circulating cortisol level	Frequent (30-79%)
HP:0005585	Spotty hyperpigmentation	Frequent (30-79%)
HP:0007565	Multiple cafe-au-lait spots	Frequent (30-79%)
HP:0010785	Gonadal neoplasm	Frequent (30-79%)
HP:0010788	Testicular neoplasm	Frequent (30-79%)
HP:0011672	Cardiac myxoma	Frequent (30-79%)
HP:0011760	Pituitary growth hormone cell adenoma	Frequent (30-79%)
HP:0030269	Increased circulating insulin-like growth factor 1 concentration	Frequent (30-79%)
HP:0030428	Cutaneous myxoma	Frequent (30-79%)
HP:0100619	Sertoli cell neoplasm	Frequent (30-79%)
HP:0100814	Blue nevus	Frequent (30-79%)
HP:0000008	Abnormal morphology of female internal genitalia	Occasional (5-29%)
HP:0000053	Macroorchidism	Occasional (5-29%)
HP:0000199	Tongue nodules	Occasional (5-29%)
HP:0000708	Atypical behavior	Occasional (5-29%)
HP:0000771	Gynecomastia	Occasional (5-29%)
HP:0000798	Oligozoospermia	Occasional (5-29%)
HP:0000822	Hypertension	Occasional (5-29%)
HP:0000978	Bruising susceptibility	Occasional (5-29%)
HP:0001007	Hirsutism	Occasional (5-29%)
HP:0001065	Striae distensae	Occasional (5-29%)
HP:0001297	Stroke	Occasional (5-29%)
HP:0001324	Muscle weakness	Occasional (5-29%)
HP:0001507	Growth abnormality	Occasional (5-29%)
HP:0001635	Congestive heart failure	Occasional (5-29%)
HP:0001907	Thromboembolism	Occasional (5-29%)
HP:0004324	Increased body weight	Occasional (5-29%)
HP:0006753	Neoplasm of the stomach	Occasional (5-29%)
HP:0010619	Fibroadenoma of the breast	Occasional (5-29%)
HP:0010732	Nodular changes affecting the eyelids	Occasional (5-29%)
HP:0012041	Decreased fertility in males	Occasional (5-29%)
HP:0012206	Abnormal sperm motility	Occasional (5-29%)
HP:0012743	Abdominal obesity	Occasional (5-29%)
HP:0012887	Ovarian serous cystadenoma	Occasional (5-29%)
HP:0025274	Ovarian dermoid cyst	Occasional (5-29%)
HP:0025318	Ovarian carcinoma	Occasional (5-29%)
HP:0025383	Dorsocervical fat pad	Occasional (5-29%)
HP:0025451	Testicular adrenal rest tumor	Occasional (5-29%)
HP:0030038	Enchondroma	Occasional (5-29%)
HP:0030072	Paranasal sinus neoplasm	Occasional (5-29%)
HP:0030075	Ductal carcinoma in situ	Occasional (5-29%)
HP:0100008	Schwannoma	Occasional (5-29%)
HP:0100013	Neoplasm of the breast	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	Carney complex
Mondo ID	MONDO:0015285
MeSH	D056733
Orphanet	1359
DOID	DOID:0050471
ICD-10-CM	D44.8
ICD-11	1051158630
NCIT	C4705
SNOMED CT	733491005
UMLS	C0406810
MedGen	140810
GARD	0001119
Is cancer (heuristic)	no

Also known as: atrial myxoma with lentigines · Carney complex · Carney Complex, type 1 · Carney Complex, type 2 · Carney syndrome · Carney’s syndrome · CNC · LAMB · lamb · lentigines, atrial myxoma, mucocutaneous myoma, blue Nevus syndrome · Myxoma - spotty pigmentation - endocrine overactivity · Myxoma-spotty pigmentation-endocrine overactivity syndrome · nevi, atrial myxoma, skin myxoma, ephelides syndrome

Data availability: 5 ClinVar variants · 1 GenCC gene-disease record · 1 cell line.

Disease family

An umbrella term covering 3 Mondo subtypes.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › Carney complex

Related subtypes (191): autosomal dominant polycystic liver disease, cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1, tuberous sclerosis, Treacher-Collins syndrome, hereditary breast ovarian cancer syndrome, autosomal dominant polycystic kidney disease, Lynch syndrome, branchio-oto-renal syndrome, autosomal dominant Aarskog syndrome, acroosteolysis dominant type, ADULT syndrome, autosomal dominant Alport syndrome, amelogenesis imperfecta type 1B, Townes-Brocks syndrome, nevoid basal cell carcinoma syndrome, blepharophimosis, ptosis, and epicanthus inversus syndrome, autosomal dominant brachyolmia, branchiooculofacial syndrome, pheochromocytoma/paraganglioma syndrome 4, cataract-aberrant oral frenula-growth delay syndrome, cherubism, autosomal dominant chondrodysplasia punctata, autosomal dominant popliteal pterygium syndrome, blepharocheilodontic syndrome, cochleosaccular degeneration-cataract syndrome, renal coloboma syndrome, Beare-Stevenson cutis gyrata syndrome, autosomal dominant vibratory urticaria, neurohypophyseal diabetes insipidus, autosomal dominant Kenny-Caffey syndrome, Rapp-Hodgkin syndrome, Ehlers-Danlos syndrome, classic type, autosomal dominant Ehlers-Danlos syndrome, vascular type, multiple endocrine neoplasia type 1, Coffin-Siris syndrome 1, isolated congenital adermatoglyphia, Flynn-Aird syndrome, Frasier syndrome, hand-foot-genital syndrome, Holt-Oram syndrome, hyperkeratosis-hyperpigmentation syndrome, autosomal dominant ichthyosis vulgaris, hyper-IgE recurrent infection syndrome 1, autosomal dominant, autosomal dominant keratitis, autosomal dominant keratitis-ichthyosis-hearing loss syndrome, LADD syndrome, trichorhinophalangeal syndrome type II, Noonan syndrome with multiple lentigines, microcephaly with or without chorioretinopathy, lymphedema, or intellectual disability, Marfan syndrome, melanoma, cutaneous malignant, susceptibility to, 2, autosomal dominant primary microcephaly, autosomal dominant progressive external ophthalmoplegia, monilethrix, Muir-Torre syndrome, autosomal dominant myoglobinuria, autosomal dominant centronuclear myopathy, nail-patella syndrome, multiple endocrine neoplasia type 2B, autosomal dominant omodysplasia, pheochromocytoma/paraganglioma syndrome 1, Pelger-Huet anomaly, multiple endocrine neoplasia type 2A, piebaldism, autosomal dominant medullary cystic kidney disease with or without hyperuricemia, generalized juvenile polyposis/juvenile polyposis coli, juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, Peutz-Jeghers syndrome, contractures, pterygia, and spondylocarpotarsal fusion syndrome 1A, autosomal dominant distal renal tubular acidosis, retinoschisis, autosomal dominant, autosomal dominant Robinow syndrome, scapuloperoneal spinal muscular atrophy, autosomal dominant, autosomal dominant sideroblastic anemia, spondyloepiphyseal dysplasia tarda, autosomal dominant, proximal symphalangism, calcaneonavicular coalition, thanatophoric dysplasia type 1, trichorhinophalangeal syndrome type I, Muckle-Wells syndrome, autosomal dominant hypophosphatemic rickets, von Hippel-Lindau disease, Denys-Drash syndrome, autosomal dominant severe congenital neutropenia, Costello syndrome, EEC syndrome, multiple cutaneous and mucosal venous malformations, diffuse nonepidermolytic palmoplantar keratoderma, Timothy syndrome, pheochromocytoma/paraganglioma syndrome 2, spondyloepimetaphyseal dysplasia with multiple dislocations, Brooke-Spiegler syndrome, macrocephaly-autism syndrome, pheochromocytoma/paraganglioma syndrome 3, Duane-radial ray syndrome, PCWH syndrome, heart-hand syndrome, Slovenian type, congenital stationary night blindness autosomal dominant 3, mandibulofacial dysostosis-microcephaly syndrome, multiple endocrine neoplasia type 4, juvenile cataract-microcornea-renal glucosuria syndrome, Crouzon syndrome-acanthosis nigricans syndrome, Birk-Barel syndrome, thrombophilia due to protein S deficiency, autosomal dominant, dyskeratosis congenita, autosomal dominant 2, dyskeratosis congenita, autosomal dominant 3, colorectal cancer, hereditary nonpolyposis, type 6, colorectal cancer, hereditary nonpolyposis, type 7, brain small vessel disease 2A, autosomal dominant, intellectual disability, autosomal dominant 14, intellectual disability, autosomal dominant 15, intellectual disability, autosomal dominant 16, hypopigmentation-punctate palmoplantar keratoderma syndrome, intellectual disability-facial dysmorphism syndrome due to SETD5 haploinsufficiency, postaxial polydactyly-anterior pituitary anomalies-facial dysmorphism syndrome, intellectual developmental disorder with microcephaly and with or without ocular malformations or hypogonadotropic hypogonadism, intellectual disability, autosomal dominant 29, intellectual disability, autosomal dominant 30, Houge-Janssens syndrome 2, severe achondroplasia-developmental delay-acanthosis nigricans syndrome, dyskeratosis congenita, autosomal dominant 6, epidermolysis bullosa simplex 6, generalized, with scarring and hair loss, autosomal dominant complex spastic paraplegia, early-onset autosomal dominant Alzheimer disease, muscular dystrophy, limb-girdle, autosomal dominant, Feingold syndrome, neuronopathy, distal hereditary motor, autosomal dominant, autosomal dominant coarctation of aorta, autosomal dominant spondylocostal dysostosis, autosomal dominant hypohidrotic ectodermal dysplasia, Cowden disease, autosomal dominant distal myopathy, autosomal dominant rhegmatogenous retinal detachment, palmoplantar keratoderma-spastic paralysis syndrome, Alagille syndrome due to a JAG1 point mutation, PTEN hamartoma tumor syndrome, gastric adenocarcinoma and proximal polyposis of the stomach, autosomal dominant proximal renal tubular acidosis, autosomal dominant spastic ataxia, Waardenburg syndrome, hereditary retinoblastoma, autosomal dominant hypocalcemia, Li-Fraumeni syndrome, Loeys-Dietz syndrome, hereditary hemorrhagic telangiectasia, hereditary inclusion body myopathy-joint contractures-ophthalmoplegia syndrome, microcephalic osteodysplastic dysplasia, Saul-Wilson type, autosomal dominant intermediate Charcot-Marie-Tooth disease, autosomal dominant cutis laxa, autosomal dominant nonsyndromic hearing loss, autosomal dominant optic atrophy, autosomal dominant Emery-Dreifuss muscular dystrophy, autosomal dominant cerebellar ataxia, autosomal dominant osteopetrosis, autosomal dominant epidermolytic ichthyosis, ventricular arrhythmias due to cardiac ryanodine receptor calcium release deficiency syndrome, distal arthrogryposis type 2B1, neurofibromatosis, autosomal dominant cataract, arthrogryposis, distal, type 2B2, arthrogryposis, distal, type 2B3, Charcot-Marie-Tooth disease, demyelinating, type 1G, Delpire-McNeill syndrome, LAMA5-related multisystemic syndrome, autosomal dominant oculocutaneous albinism, Charcot-Marie-tooth disease, axonal, type 2DD, Pilarowski-Bjornsson syndrome, intellectual disability, autosomal dominant, fatty acyl-CoA reductase 1 upregulation, GUCY2D-related dominant retinopathy, RPE65-related dominant retinopathy, autosomal dominant titinopathy, NOG-related symphalangism spectrum disorder, ALPL-related autosomal dominant hypophosphatasia, MYH10-related neurodevelopmental disorder with congenital anomalies, spastic paraplegia 30A, autosomal dominant, TMEM127-related tumor predisposition, MAX-related tumor predisposition, BMPR1A-related juvenile polyposis syndrome, RP1-related dominant retinopathy, Birt-Hogg-Dube syndrome, inclusion body myopathy and brain white matter abnormalities, KINSSHIP syndrome, autosomal dominant nebulin-related myopathy, IMPG1-related dominant retinopathy, PROM1-related dominant retinopathy, PURA-related severe neonatal hypotonia-seizures-encephalopathy syndrome, ALG8-related autosomal dominant polycystic kidney and/or liver disease, NOTCH1-related AOS spectrum disorder, FLNB-associated autosomal dominant filamin related bone disorder, familial antiphospholipid syndrome

Subtypes (3): Carney complex, type 1, Carney complex type 2, Carney complex - trismus - pseudocamptodactyly syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

5 retrieved; paginated sample, class counts are floors:

4 pathogenic, 1 uncertain significance

ClinVar	Variant (HGVS)	Gene	Classification	Review
164995	NM_002734.5(PRKAR1A):c.623del (p.Gly208fs)	PRKAR1A	Pathogenic	criteria provided, multiple submitters, no conflicts
29907	NM_002734.5(PRKAR1A):c.1102C>T (p.Arg368Ter)	PRKAR1A	Pathogenic	criteria provided, multiple submitters, no conflicts
379923	NM_002734.5(PRKAR1A):c.535C>T (p.Gln179Ter)	PRKAR1A	Pathogenic	criteria provided, multiple submitters, no conflicts
41391	NM_002734.5(PRKAR1A):c.682C>T (p.Arg228Ter)	PRKAR1A	Pathogenic	criteria provided, multiple submitters, no conflicts
12674	NM_002734.5(PRKAR1A):c.220C>T (p.Arg74Cys)	PRKAR1A	Uncertain significance	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 19 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
PRKAR1A	Definitive	Autosomal dominant	Carney complex, type 1	19

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
PRKAR1A	Orphanet:1359	Carney complex
PRKAR1A	Orphanet:1501	Adrenocortical carcinoma
PRKAR1A	Orphanet:520	Acute promyelocytic leukemia
PRKAR1A	Orphanet:615	Familial atrial myxoma
PRKAR1A	Orphanet:647772	Isolated primary pigmented nodular adrenocortical disease
PRKAR1A	Orphanet:950	Acrodysostosis

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
PRKAR1A	HGNC:9388	ENSG00000108946	P10644	cAMP-dependent protein kinase type I-alpha regulatory subunit	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
PRKAR1A	cAMP-dependent protein kinase type I-alpha regulatory subunit	Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Other/Unknown	1	1.8×	0.558

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
PRKAR1A	Other/Unknown	no		cNMP-bd_dom, cAMP_dep_PK_reg_su_I/II_a/b, cAMP_dep_PK_reg_su

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
germinal epithelium of ovary	1
lateral nuclear group of thalamus	1
mucosa of paranasal sinus	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
PRKAR1A	295	ubiquitous	marker	mucosa of paranasal sinus, germinal epithelium of ovary, lateral nuclear group of thalamus

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PRKAR1A	3,586

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
PRKAR1A	P10644	3

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 52. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
ALK mutants bind TKIs	1	951.7×	0.008	PRKAR1A
CREB1 phosphorylation through the activation of Adenylate Cyclase	1	878.5×	0.008	PRKAR1A
PKA activation in glucagon signalling	1	671.8×	0.008	PRKAR1A
PKA activation	1	634.4×	0.008	PRKAR1A
PKA-mediated phosphorylation of CREB	1	571.0×	0.008	PRKAR1A
DARPP-32 events	1	475.8×	0.008	PRKAR1A
Anti-inflammatory response favouring Leishmania parasite infection	1	393.8×	0.008	PRKAR1A
Leishmania parasite growth and survival	1	393.8×	0.008	PRKAR1A
Calmodulin induced events	1	380.7×	0.008	PRKAR1A
CaM pathway	1	380.7×	0.008	PRKAR1A
Ca-dependent events	1	368.4×	0.008	PRKAR1A
Aquaporin-mediated transport	1	368.4×	0.008	PRKAR1A
Glucagon signaling in metabolic regulation	1	346.1×	0.008	PRKAR1A
G-protein mediated events	1	326.3×	0.008	PRKAR1A
DAG and IP3 signaling	1	317.2×	0.008	PRKAR1A
Response of endothelial cells to shear stress	1	300.5×	0.008	PRKAR1A
FCGR3A-mediated IL10 synthesis	1	292.8×	0.008	PRKAR1A
Signaling by ALK in cancer	1	271.9×	0.008	PRKAR1A
Opioid Signalling	1	265.6×	0.008	PRKAR1A
PLC beta mediated events	1	265.6×	0.008	PRKAR1A
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	1	265.6×	0.008	PRKAR1A
Vasopressin regulates renal water homeostasis via Aquaporins	1	265.6×	0.008	PRKAR1A
Cellular responses to mechanical stimuli	1	259.6×	0.008	PRKAR1A
ADORA2B mediated anti-inflammatory cytokines production	1	253.8×	0.008	PRKAR1A
GPER1 signaling	1	248.3×	0.008	PRKAR1A
Regulation of insulin secretion	1	219.6×	0.009	PRKAR1A
Post NMDA receptor activation events	1	203.9×	0.009	PRKAR1A
Activation of NMDA receptors and postsynaptic events	1	184.2×	0.010	PRKAR1A
Signaling by Hedgehog	1	184.2×	0.010	PRKAR1A
Hedgehog ‘off’ state	1	178.4×	0.010	PRKAR1A

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
negative regulation of activated T cell proliferation	1	1053.2×	0.004	PRKAR1A
cellular response to glucagon stimulus	1	842.6×	0.004	PRKAR1A
vascular endothelial cell response to laminar fluid shear stress	1	732.7×	0.004	PRKAR1A
negative regulation of inflammatory response to antigenic stimulus	1	601.9×	0.004	PRKAR1A
negative regulation of cAMP/PKA signal transduction	1	601.9×	0.004	PRKAR1A
cardiac muscle cell proliferation	1	581.1×	0.004	PRKAR1A
renal water homeostasis	1	510.7×	0.004	PRKAR1A
mesoderm formation	1	495.6×	0.004	PRKAR1A
sarcomere organization	1	383.0×	0.004	PRKAR1A
positive regulation of insulin secretion	1	255.3×	0.006	PRKAR1A
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1	113.1×	0.012	PRKAR1A
chemical synaptic transmission	1	77.3×	0.016	PRKAR1A
negative regulation of gene expression	1	69.1×	0.017	PRKAR1A
intracellular signal transduction	1	38.1×	0.028	PRKAR1A
regulation of transcription by RNA polymerase II	1	11.7×	0.086	PRKAR1A

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
PRKAR1A	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
PRKAR1A	2	Binding:2

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	PRKAR1A

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
PRKAR1A	2	—

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01560260	PHASE2	COMPLETED	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
NCT03050268	Not specified	RECRUITING	Familial Investigations of Childhood Cancer Predisposition
NCT06523582	Not specified	RECRUITING	Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
NCT00001452	Not specified	COMPLETED	Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LINSITINIB	3	1